Ikarian Capital, established in Dallas, has Neil Shahrestani as its Chief Investment Officer, managing member, and co-founder. The biotechnology and pharmaceuticals firms are the primary investments of the hedge fund. He earned an honors degree in economics from Columbia University and an honors degree in medicine from Harvard Medical School. The majority of Ikarian Capital’s investments are in the banking and healthcare sectors. As of the conclusion of the first quarter of 2021, the hedge fund’s 13F portfolio was worth around $2.96 billion. Eli Lilly & Company and AstraZeneca PLC are two of these companies. The banking and healthcare sectors account for the majority of Ikarian Capital’s investments. As of the conclusion of the first quarter of 2021, the hedge fund’s 13F portfolio is worth roughly $2.96 billion. Eli Lilly & Company and AstraZeneca PLC are two examples of these businesses.
Here is Insider Monkey’s list of the 10 best stocks to buy according to Neil Shahrestani’s Ikarian Capital. Lyra Therapeutics, Inc. is a clinical-stage pharmaceutical company that develops and markets new integrated medications for the localized treatment of ear, nose, and throat diseases. Lyra presently has a market capitalization of $83.73 million. According to Neil Shahrestani’s Ikarian Capital, Vaxcyte, Inc. is the ninth best stock to purchase. Over the last three months, shares have provided investors with returns of more than 22%. Relmada Therapeutics, Inc. is the eighth best stock to buy. The company was founded in 2004 and has a market capitalization of $436.7 million. Militestone Pharmaceuticals Inc. is one of the best companies to buy. The company specializes in cardiovascular drugs and is ranked seventh among the top ten stocks to invest in. Prothena Corporation Plc is the sixth best stock to purchase. Over the last three months, Prothena shares have returned 312.46 percent to investors. For more details, click 10 Stocks to Buy According to Neil Shahrestani’s Ikarian Capital.